SUBTYPE C HIV ANTIGEN: MULTIVALENT & PRIME-BOOST REGIMEN

C 亚型 HIV 抗原：多价

• 批准号: 6534230
• 负责人: FARUK M SINANGIL
• 金额: $ 49.6万
• 依托单位: VAXGEN, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-29 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6534230
• 关键词: AIDS vaccines; HIV envelope protein gp120; Macaca; genetic polymorphism; human immunodeficiency virus 1; human subject; molecular cloning; neutralizing antibody; nucleic acid sequence; protein purification; vaccine development; virus antigen

Given the enormous number of HIV-infected people worldwide, most epidemiologists agree that a vaccine is the only practical solution to stemming the AIDS epidemic. Although a number of different strategies could be utilized, no strategy has yet been proven to elicit a better immune response than one based on the envelope glycoprotein, gp120. These vaccines exhibit almost all the technical characteristics of an ideal vaccine. They elicit neutralizing antibodies effective against both macrophage tropic and T cell tropic strains of HIV-1. They are capable of stimulating antibodies reactive with the common polymorphisms, appear safe, and are affordable for worldwide distribution. Our goal is to generate H1V subtype C gp120 protein antigens to use in either a multivalent vaccine or as a component of a prime-boost regimen. Virus will be collected and cloned and their respective gp120 genes will be sequenced. The sequence analysis will be used to identify the polymorphisms within the neutralizing epitopes. The bioinformatic results will guide the selection of gp120 molecules that will be transiently expressed and purified. A high throughput neutralization assay will be developed in order to examine a large number of antigen combinations in a timely manner. PROPOSED COMMERCIAL APPLICATION: The potential commercial application of this research is a subtype C HIV vaccine.

鉴于全世界艾滋病毒感染者的数量巨大，大多数流行病学家都认为疫苗是遏制艾滋病流行的唯一实际解决方案。尽管可以利用许多不同的策略，但是还没有任何策略被证明比基于包膜糖蛋白gp 120的策略引起更好的免疫应答。这些疫苗表现出理想疫苗的几乎所有技术特征。它们可引发有效对抗HIV-1嗜巨噬细胞和嗜T细胞株的中和抗体。它们能够刺激与常见多态性反应的抗体，似乎是安全的，并且在全球范围内销售是负担得起的。我们的目标是产生H1 V亚型C gp 120蛋白抗原，用于多价疫苗或作为初免-加强方案的组成部分。将收集并克隆病毒，并对其各自的gp 120基因进行测序。序列分析将用于鉴定中和表位内的多态性。生物信息学的结果将指导选择的gp 120分子，将瞬时表达和纯化。将开发高通量中和试验，以便及时检查大量抗原组合。拟议的商业应用：这项研究的潜在商业应用是C亚型HIV疫苗。

项目成果

Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.

• DOI: 10.1371/journal.pone.0012076
• 发表时间: 2010-08-11
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Smith DH;Winters-Digiacinto P;Mitiku M;O'Rourke S;Sinangil F;Wrin T;Montefiori DC;Berman PW
• 通讯作者: Berman PW